

## Curriculum Vitae

1. **Date:** May 2020

### I. PERSONAL:

2. **Name:**

Barbara J. Mason

3. **Cell Phone:**

858-504-0905

4. **Office Phone:**

858-784-7328

5. **Address (*office*):**

Department of Molecular Medicine  
The Scripps Research Institute  
10550 N. Torrey Pines Road, TPC-5  
La Jolla, CA 92037

6. **Current Academic Rank:**

Professor with Tenure

7. **Primary Department:**

Department of Molecular Medicine

8. **Secondary/Joint Appointment:**

Adjunct Professor, Department of Psychiatry  
University of California, San Diego

Adjunct Professor, Department of Psychiatry and Behavioral Sciences  
University of Miami Miller School of Medicine, Miami, FL

9. **Citizenship:**

USA

10. **Visa Type (*if non citizen*):**

N/A

### II. HIGHER EDUCATION:

11. **Institutional (*institution; degree; date conferred*):**

Weill Cornell University Medical College Department of Psychiatry; Postdoctoral Fellow in Psychopharmacology; 1983-1987

Long Island University; Ph.D., Clinical Psychology; 1983

Pratt Institute; B.F.A., Bachelor of Fine Arts; 1972

12. **Non-Institutional (*description; dates*):**

MacArthur Foundation Research Network 1: Psychobiology of Depression Genetics Training Workshop; 1991

Interpersonal Psychotherapy of Depression; 1987

Clinical Neuropsychology and the Halstead Reitan; 1980-1982

The Roosevelt Hospital/Smither Center Physicians' Training Program on Alcoholism; 1979

Institute of Psychoanalytic Training and Research; 1974-1976

**13. Certification, Licensure (*description; board or agency; dates*):**

Clinical Psychologist; New York State, No. 007896; granted 1983

Clinical Psychologist; Florida, No. PY4630; granted 1991

Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders; American Psychological Association, No. AD002813; granted 1996

**III. EXPERIENCE:**

**14. Academic (*institution; rank/status; dates*):**

2016-present The Scripps Research Institute Kellogg School of Science and Technology, La Jolla, CA; Faculty and Course Director, Graduate Program

2014-2017 The Scripps Research Institute, La Jolla, CA; Chair, Committee on the Neurobiology of Addictive Disorders

2009-present University of California San Diego, La Jolla, CA; Adjunct Professor, Department of Psychiatry

2003-present The Scripps Research Institute, La Jolla, CA; Professor with Tenure, Departments of Molecular Medicine and Neuroscience, formerly the Committee on the Neurobiology of Addictive Disorders (2006-2017); Molecular and Integrative Neurosciences Department (2005-2006); Department of Neuropharmacology (2003-2005)

2003-present The Scripps Research Institute, La Jolla, CA; The Pearson Center for Alcoholism and Addiction Research (Director, 2014-present; Co-Director, 2003-2013)

2003-present The Scripps Research Institute, La Jolla, CA; Director, Laboratory of Clinical Psychopharmacology

2003-present University of Miami School of Medicine, Miami, FL; Adjunct Professor, Department of Psychiatry and Behavioral Sciences

2000-2003	University of Miami School of Medicine, Miami, FL; Professor with Tenure, Department of Psychiatry and Behavioral Sciences
1997-2000	University of Miami School of Medicine, Miami, FL; Associate Professor with Tenure, Department of Psychiatry and Behavioral Sciences
1993-2003	University of Miami School of Medicine, Miami, FL; Director, Division of Substance Abuse, Department of Psychiatry and Behavioral Sciences
1992-1993	University of Miami School of Medicine, Miami, FL; Chief of Training and Research, Section on Alcohol and Drug Abuse, Department of Psychiatry and Behavioral Sciences
1992-2003	Mount Sinai Medical Center, Miami Beach, FL; Attending Psychologist in Psychiatry
1992-2003	The Rockefeller University, New York, NY; Adjunct Faculty
1991-1997	University of Miami School of Medicine, Miami, FL; Associate Professor, Department of Psychiatry and Behavioral Sciences
1991-2003	University of Miami School of Medicine, Miami, FL; Director, Alcohol Disorders Research Clinic, Department of Psychiatry and Behavioral Sciences
1990-1991	New York Hospital-Cornell Medical Center, New York, NY; Chief, Alcohol Disorders Clinic, Department of Psychiatry
1987-1991	Cornell University Medical College, New York, NY; Assistant Professor of Psychology, Department of Psychiatry
1987-1991	New York Hospital-Cornell Medical Center; Assistant Attending Psychologist in Psychiatry
1984-1987	Cornell University Medical College, New York, NY; Instructor of Psychology, Department of Psychiatry
1981-1984	Cornell University Medical College, New York, NY; Research Associate, Department of Psychiatry
1981-1984	Long Island University, Brooklyn, NY; Assistant Professor of Psychology
1980-1981	Roosevelt Hospital-St. Lukes Medical Center, New York, NY; Psychology Intern

**15. Non-Academic (*employers; title; responsibilities; dates*):**

National Institute on Drug Abuse Intramural Research Program (NIDA-IRP); Member, Medications Development Program (MDP) Advisory Board; 2014-present

National Institutes of Health (NIH); Member, National Advisory Council on Drug Abuse; 2012-2014

National Institute on Drug Abuse (NIDA); Meeting Participant, CTN Protocol Review Board; 2012

National Institute on Drug Abuse (NIDA); Member, Medications Development Centers of Excellence Special Emphasis Panel; 2009

National Institute on Alcohol Abuse and Alcoholism (NIAAA); Member, Special Emphasis Panel; 2008

National Institute on Alcohol Abuse and Alcoholism (NIAAA); Member, Clinical and Treatment Subcommittee Special Emphasis Panel; 2007

National Institute on Drug Abuse (NIDA); Member, Pilot Clinical Trials Special Emphasis Panel; 2006

NIAAA/NIDA/NIMH; Participant, Workshop – Methodology of Conducting Pharmacologic Clinical Trials in Patients with Alcohol/Drug Dependence and Psychiatric Comorbidity; 2006

National Institute on Alcohol Abuse and Alcoholism (NIAAA); Member, Extramural Advisory Board; 2005

National Institute on Drug Abuse (NIDA); Member, Medication Development Center Application Review Group; 2004

National Institutes of Health (NIH); Ad Hoc Member, Government Performance and Results Act (GPRA) Review Group; 2000

Food and Drug Administration, Division of Anesthetic Critical Care and Addiction Drug Products; Guest Expert, Scientific Advisory Council; 1998

National Institute on Alcohol Abuse and Alcoholism (NIAAA); Member, National Advisory Council; 1998-2002

National Institute on Drug Abuse (NIDA); Consultant, Medications Development Division's Clinical Cocaine Treatment Program; 1995-1997

National Institute on Alcohol Abuse and Alcoholism (NIAAA); Member, Clinical and Treatment Subcommittee Initial Review Group; 1993-1997

**16. Military (*branch; rank; responsibilities; dates*):**

N/A

**IV. PUBLICATIONS:**

**17. Juried or refereed journal articles or exhibitions:**

Ray, L.A., Grodin, E., Leggio, L., Bechtholt, A., Becker, H., Feldstein Ewing, S., Jentsch, J.D., King, A., Mason, B., O'Malley, S., MacKillop, J., Heilig, M., & Koob, G. The future of translational research on alcohol use disorder. Addiction Biology. 2020;e12903. <https://doi.org/10.1111/adb.12903>. (*in press*)

Loflin, M. J. E., Kiluk, B. D., Huestis, M. A., Aklin, W. M., Budney, A. J., Carroll, K. M., D'Souza, D. C., Dworkin, R. H., Gray, K. M., Hasin, D. S., Lee, D. C., Le Foll, B., Levin, F. R., Lile, J. A., Mason, B. J., McRae-Clark, A. L., Montoya, I., Peters, E. N., Ramey, T., ... Strain, E. C. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and alcohol dependence, [107993]. <https://doi.org/10.1016/j.drugalcdep.2020.107993> (*Accepted/in press*).

Falk, D.E., Ryan, M.L., Fertig, J.B., Devine, E.G., Cruz, R., Brown, E., Burns, H., Salloum, I.M., Newport, D.J., Mendelson, J., Galloway, G., Kampman, K., Brooks, C., Green, A.I., Brunette, M.F., Rosenthal, R.N., Dunn, K.E., Strain, E.C., Ray, L., Shoptaw, S., Ait-Daoud Tiouririne, N., Gunderson, E.W., Ransom, J., Scott, C., Leggio, L., Caras, S., Mason, B.J., Litten, R.Z. and National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG). Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Re, 2019; 43:158-169. doi:10.1111/acer.13917

Mason, B.J., Quello, S., Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs; 2018; 27(1):113-124

Mason, B.J. Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology; 2017; 122:244-253

Koob, G.F. and Mason, B.J. Existing and Future Drugs for the Treatment of the Dark Side of Addiction. Annual Review of Pharmacology and Toxicology; 2016; 56:299-322

Mason, B.J. Acamprosate, alcoholism, and abstinence. Journal of Clinical Psychiatry; 2015; 76(2):e224-e225

Vendruscolo, L.F., Estey, D., Goodell, V., Macshane, L.G., Logrip, M.L., Schlosburg, J.E., McGinn, M.A., Zamora-Martinez, E.R., Belanoff, J.K., Hunt, H.J., Sanna, P.P., George, O., Koob, G.F., Edwards, S., Mason, B.J. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. The Journal of Clinical Investigation; 2015; 125(8):3193-3197

Perney, P., Rigole, H., Mason, B., Dematteis, M., Leher, P. Measuring sleep disturbances in patients with alcohol use disorders: A short questionnaire suitable for routine practice. Journal of Addiction Medicine; 2015; 9(1):25-30

Araos, P., Pedraz, M., Serrano, A., Lucena, M., Barrios, V., Garcia-Marchena, N., Campos-Cloute, R., Ruiz, J.J., Romero, P., Suarez, J., Baixeras, E., de la Torre, R., Montesinos, J., Guerri, C., Rodriguez-Arias, M., Minarro, J., Martinez-Riera, R., Torrens, M., Chowen, J.A., Argente, J., Mason, B.J., Pavon, F., Rodriguez de Fonseca, F. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addiction Biology; 2015; 20(4):756-72. doi: 10.1111/adb.12156 Epub 2014 May 22.

Mason, B.J., Quello, S., Goodell, V., Shadan, F., Kyle, M., Begovic, A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Internal Medicine; 2014; 174:70-77

**Note: Results served as the basis for a pivotal trial of Horizant (gabapentin enacarbil) conducted in support of FDA approval as a new treatment for alcohol dependence.**

Mason, B.J., Crean, R., Goodell, V., Light, J.M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., Rao, S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology; 2012; 37:1689-1698

**Note: This is the only positive treatment study for both cannabis use and withdrawal.**

Higley, A.E., Koob, G.F., Mason, B.J. Treatment of alcohol dependence with drug antagonists of the stress response. Alcohol Research: Current Reviews; 2012; 34:516-521

Perney P., Leher, P., Mason, B.J. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. Alcohol and Alcoholism; 2012; 47:133-139

Mason, B.J., Leher, P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcoholism: Clinical and Experimental Research; 2012; 36:497-508

Higley, A.E., Crane, N.A., Spadoni, A.D., Quello, S.B., Goodell, V., Mason, B.J. Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology; 2011; 218:121-129

Crean, R.D., Tapert, S.F., Minassian, A., MacDonald, K., Crane, N.A., Mason, B.J. Effects of chronic, heavy cannabis use on executive functions. Journal of Addiction Medicine; 2011; 5:9-15

Crean, R.D., Crane, N.A., Mason, B.J. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine; 2011; 5:1-8

Mason, B.J., Heyser, C.J. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS & Neurological Disorders – Drug Targets; 2010; 9:23-32

Mason, B.J., Leher, P. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. The American Journal on Addictions; 2010; 19:147-154

Mason, B.J., Heyser, C.J. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opinion on Drug Safety; 2010; 9:177-188

Mason, B.J., Shaham, Y., Weiss, F., Le, A.D. Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets. Alcohol; 2009; 43:541-543

Mason, B.J., Leher, P. Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. Journal of Addiction Medicine; 2009; 3:164-171

Koob, G.F., Lloyd, G.K., Mason, B.J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nature Reviews. Drug Discovery; 2009; 8:500-515

Mason, B.J., Light, J.M., Williams, L.D., Drobos, D.J. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addiction Biology; 2009; 14:73-83

**Note: This paper is part of a special issue of Addiction Biology co-edited by Dr. Mason devoted to human laboratory approaches to addiction research.**

Mason, B.J., Light, J.M., Escher, T., Drobos, D.J. Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology; 2008; 200:141-150

Donovan, D.M., Anton, R.F., Miller, W.R., Longabaugh, R., Hosking, J.D., Youngblood, M., COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. Journal of Studies on Alcohol and Drugs; 2008; 69:5-13

Mason, B.J., Crean, R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Review of Neurotherapeutics; 2007; 7:1465-1477

Mason, B.J. Acamprosate for alcohol dependence: an update for the clinician. FOCUS; 2006; 4:505-511

Mason, B.J., Goodman, A.M., Chabac, S., Lehert, P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. Journal of Psychiatric Research; 2006; 40:383-393

**Note: This 21-site study was conducted in support of FDA approval for acamprosate (Campral) treatment of alcohol dependence. Dr. Mason served as overall PI and was instrumental in the design of the protocol and counseling materials, which are available at [www.alcoholfree.info](http://www.alcoholfree.info).**

Anton, R.F., O'Malley, S.S., Ciraulo, D.A., Cisler, R.A., Couper, D., Donovan, D.M., Gastfriend, D.R., Hosking, J.D., Johnson, B.A., LoCastro, J.S., Longabaugh, R., Mason, B.J., Mattson, M.E., Miller, W.R., Pettinati, H.M., Randall, C.L., Swift, R., Weiss, R.D., Williams, L.D., Zweben, A.; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE Study: a randomized controlled trial. Journal of the American Medical Association; 2006; 295:2003-2017

Johnson, B.A., Koob, G.F., Schuckit, M.A., Mason, B.J., Ait-Daoud, N. Understanding and treating alcohol dependence. Alcoholism: Clinical and Experimental Research; 2006; 30:567-584

Kranzler, H.R., Mueller, T., Cornelius, J., Pettinati, H.M., Moak, D., Martin, P.R., Anthenelli, R., Brower, K.J., O'Malley, S., Mason, B.J., Hasin, D., Keller, M. Sertraline treatment of co-occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology; 2006; 26:13-20

Mason, B.J. Acamprosate in the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy; 2005; 6:2103-2115

Mason, B.J. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. Journal of Studies on Alcohol; 2005; Supplement 15:148-156

O'Malley S.S., Martin, D.J., Hosking J., Mason, B.J. How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE study. Journal of Studies on Alcohol; 2005; Supplement 15:66-71

Mason, B.J. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. European Neuropsychopharmacology; 2003; 13:469-475

COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): a pilot feasibility study. Alcoholism: Clinical and Experimental Research; 2003; 27:1123-1131

COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcoholism: Clinical and Experimental Research; 2003; 27:1107-1122

Mason, B.J. Acamprosate. Recent Developments in Alcoholism; 2003; 16:203-215

Mason, B.J., Goodman, A.M., Dixon, R.M., Abdel Hameed, M.H., Hulot, T., Wesnes, K., Hunter, J.A., Boyeson, M.G. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology; 2002; 27:596-606

**Note: This was the first interaction study of these two new medications for alcohol dependence.**

Koob, G.F., Mason, B.J., De Witte, P., Littleton, J., Siggins, G.R. Potential neuroprotective effects of acamprosate. Alcoholism: Clinical and Experimental Research; 2002; 26:586-592

Xie, S., Suckow, R.F., Mason, B.J., Allen, D., Cooper, T.B. Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry. Journal of Chromatography; 2002; 773:143-149

Mason, B.J. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. Journal of Clinical Psychiatry; 2001; 62(20):42-48

Boening, J.A., Lesch, O.M., Spanagel, R., Wolffgramm, J., Narita, M., Sinclair, D., Mason, B.J., Wiesbeck, G.A. Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. Alcoholism: Clinical and Experimental Research; 2001; 25(5 Suppl ISBRA):127S-131S

Mason, B.J., Ownby, R.L. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums; 2000; 5:58-69

Mason, B.J., Salvato, F.R., Williams, L.D., Ritvo, E.C., Cutler, R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Archives of General Psychiatry; 1999; 56:719-724

**Note: NIH chose this project for presentation by Dr. Varmus, Director of NIH, to the U.S. Congress as a pivotal study of 1999. Nalmefene has subsequently received EMA approval as a new treatment for Alcohol Use Disorder throughout the European Union.**

Mason, B.J., Kocsis, J.H., Melia, D., Khuri, E.T., Sweeney, J., Wells, A., Borg, L., Millman, R.B., Kreek, M.J. Psychiatric comorbidity in methadone maintained patients. Journal of Addictive



Diseases; 1998; 17:75-89

Mason, B.J., Kocsis, J.H., Ritvo, E.C., Cutler, R.B. A double-blind, placebo-controlled trial of desipramine in primary alcohol dependence stratified on the presence or absence of major depression. Journal of the American Medical Association; 1996; 275:761-767

**Note: This project was chosen by the American Medical Association (AMA) to be the lead article in JAMA and was the focus of an AMA media briefing. This work was described by Alan Gelenberg, M.D., in the *Biological Therapies in Psychiatry Newsletter* as “a landmark work of major public health significance.”**

Mason, B.J. Dosing issues in the pharmacotherapy of alcoholism. Alcoholism: Clinical and Experimental Research; 1996; 20(Supplement 7):10A-16A

**Note: This project was part of an Alcoholism: Clinical and Experimental Research supplement for which Dr. Mason served as Guest Editor.**

Williams, L.D., Mason, B.J., Goldberg, G., Cutler, R.B. Women and minorities representation in alcoholism treatment research. Psychopharmacology Bulletin; 1996; 32:201-204

Johnson, B.A., Jasinski, D.R., Galloway, G.P., Kranzler, H., Weinreib, R., Anton, R.F., Mason, B.J., Bohn, M.J., Pettinati, H.M., Rawson, R., Clyde, C. Ritanerlin in the treatment of alcohol dependence - a multi-center trial. Psychopharmacology; 1996; 128:206-215

Ownby, R.L., Mason, B.J., Eisdorfer, C. Alcohol abuse among older adults and the elderly. Journal of Practical Psychiatry and Behavioral Health; 1996; 2:216-222

Mason, B.J., Ritvo, E.C., Morgan, R.O., Salvato, F.R., Goldberg, G., Welch, B., Mantero-Atienza, E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcoholism: Clinical and Experimental Research; 1994; 18:1162-1167

Salvato, F.R., Mason, B.J. Changes in transaminases over the course of a 12-week double-blind nalmefene trial in a 38-year old female subject. Alcoholism: Clinical and Experimental Research; 1994; 18:1187-1189

Mason, B.J., Kocsis, J.H., Leon, A.C., Thompson, S., Frances, A.J., Morgan, R.O., Parides, M.K. Measurement of severity and treatment response in dysthymia. Psychiatric Annals; 1993; 23:625-631

Mason, B.J. Depression in alcoholism: diagnosis and treatment. Science Matters; 1992; 2:33-36

Mason, B.J., Kocsis, J.H. Desipramine treatment of alcoholism. Psychopharmacology Bulletin; 1991; 27:155-161

Mason, B.J., Kocsis, J.H., Frances, A.J., Mann, J.J. Amoxapine versus amitriptyline for continuation therapy of depression. Journal of Clinical Psychopharmacology; 1990; 10:338-343

Kocsis, J.H., Mason, B.J., Frances, A.J., Sweeney, J., Mann, J.J., Marin, D. Prediction of response of chronic depression to imipramine. Journal of Affective Disorders; 1989; 17:255-260

- Frances, A., Kocsis, J., Marin, D., Manning, D., Markowitz, J., Mason, B., Widiger, T. Diagnostic criteria for dysthymic disorder. Psychopharmacology Bulletin; 1989; 25:325-329
- Kocsis, J.H., Frances, A.J., Voss, C., Mason, B.J., Mann, J.J., Sweeney, J. Imipramine and social-vocational adjustment in chronic depression. American Journal of Psychiatry; 1988; 145:997-999
- Kocsis, J.H., Frances, A.J., Voss, C., Mann, J.J., Mason, B.J., Sweeney, J. Imipramine treatment for chronic depression. Archives of General Psychiatry; 1988; 45:253-257
- Mason, B.J., Kocsis, J.H. Methods and issues in psychopharmacological studies. Drugs and Society; 1988; 2:83-91
- Kocsis, J.H., Kennedy, S., Brown, R.P., Mann, J.J., Mason, B. Suicide and adrenocortical function. Psychopharmacology Bulletin; 1986; 22:650-655
- Brown, R.P., Mason, B., Stoll, P., Brizer, D., Kocsis, J.H., Stokes, P., Mann, J.J. Adrenocortical function and suicidal behavior in depressive disorders. Psychiatry Research; 1986; 17:317-323
- Kocsis, J.H., Frances, A., Mann, J.J., Sweeney, J., Voss, C., Mason, B., Brown, R.P. Imipramine for treatment of chronic depression. Psychopharmacology Bulletin; 1985; 21:698-700
- Escobar, J.I., Mann, J.J., Keller, J., Wilkins, J., Mason, B., Mills, M.J. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Journal of Clinical Psychiatry; 1985; 46:15-19
- Exner, J.E., Jr., Thomas, E.A., Mason, B. Children's Rorschachs: description and prediction. Journal of Personality Assessment; 1985; 49:13-20
- Mason, B.J., Cohen, J.B., Exner, J.E., Jr. Schizophrenic, depressive, and nonpatient personality organizations described by Rorschach factor structures. Journal of Personality Assessment; 1985; 49:295-305

## **18. Book chapters and monographs published:**

- Mason, B.J. Anticonvulsants to Treat Cannabis Use Disorder. In Cannabis Use Disorders (Montoya, I.D., Weiss, S.R.B., Eds.). DOI:10.1007/978-3-319-90365-1, Springer Nature Switzerland AG, Cham, Switzerland; 2019; 21:213-220.
- Mason, B.J. Pharmacological Treatment of Alcohol Use Disorder. In APA Handbook of Psychopharmacology (Evans, S.M., Ed.). American Psychological Association, Washington, DC; 2019;481-505.
- Mason, B.J., Heyser, C.J. Acamprosate. In Encyclopedia of Psychopharmacology (Stolerman, I., Ed.). DOI:10.1007/978-3-642-27772-6\_163-2, Springer, Berlin, Heidelberg; 2014; 1-5
- Mason, B.J., Higley, A.E. Acamprosate for alcohol dependence. In Interventions for Addiction: Comprehensive Addiction Behaviors and Disorders. (Miller, P., Ed.). Elsevier, Inc., San Diego: Academic Press; 2013; 3:385-389.

Mason, B.J., Higley, A.E. A translational approach to novel medication development for protracted abstinence. In Current Topics in Behavioral Neurosciences – Behavioral Neurobiology of Alcohol Addiction book series (Sommer W. and Spanagel, R., Eds.). Springer-Verlag, Berlin Heidelberg; 2013; 13:647-670

Mason, B.J., Higley, A.E. Human laboratory models of addiction. In Food and Addiction: A Comprehensive Handbook (Brownell, K.D. and Gold, M.S., Eds.). Oxford University Press, New York, NY; 2012; Part 1:14-19

Mason, B.J., Heyser, C.J. Acamprosate. In Encyclopedia of Psychopharmacology (Stolerman, I., Ed.). Springer, Berlin, Heidelberg; 2010; 5-8

Mason, B.J., Jacobs, M. The new pharmacotherapies for alcohol dependence. In Clinical Addiction Psychiatry (Brizer, D. and Castenada, R., Eds.). Cambridge University Press, New York, NY; 2010; 188-206

Mason, B.J., Ownby, R.L. Alcohol. In Mania: Clinical and Research Perspectives (Goodnick, P.J., Ed.), American Psychiatric Press, Inc., Washington, DC; 1998; 63-80

Mason, B.J., Goodman, A. M. Brief Intervention and Medication Compliance Procedures Therapist's Manual; Lipha Pharmaceuticals, Inc., New York, NY; 1997

Kranzler, H.R., Mason, B.J., Modesto-Lowe, V. Prevalence, Diagnosis, and Treatment of Comorbid Mood Disorders and Alcoholism. In Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders (Kranzler, H.R. and Rounsaville, B.J., Eds.), Marcel Dekker, Inc., New York, NY; 1997; 107-136

Kranzler, H.R., Mason, B.J., Pettinati, H., Anton, R.F. Methodological Issues in Pharmacotherapy Trials with Alcoholics. In The Handbook of Psychopharmacology Trials: An Overview of Scientific, Political, and Ethical Concerns (Hertzman, M. and Fettner, D., Eds.), New York University Press; 1997; 213-245

Ownby, R.L., Mason, B.J. Treatment of Dysthymia. In Clinical Depression During Addiction Recovery: Process, Diagnosis and Treatment (Kantor, J.S., Ed.). Marcel Dekker, Inc., New York, NY; 1996; 63-79

Mason, B.J., Kocsis, J.H., Leon, A.C., Thompson, S., Frances, A.J., Morgan, R.O., Parides, M.K. Assessment of Symptoms and Change in Dysthymia Disorder. In Diagnosis and Treatment of Chronic Depression (Kocsis, J.H., Klein, D.N., Eds.), Guilford Press; 1995; 73-88

Klerman, G.L., Weissman, M.W., Markowitz, J., Glick, I., Wilner, P.J., Mason, B., Shear, K. Medication and Psychotherapy. In Handbook of Psychotherapy and Behavior Change, Fourth Edition (Bergin, A.E. and Garfield, S.L., Eds.), American Psychiatric Press, Inc., Washington, DC; 1993; 734-782

Mason, B.J., Markowitz, J.C., Klerman, G.L. IPT for Dysthymic Disorder. In New Applications of

Interpersonal Psychotherapy (Klerman, G.L. and Weissman, M.M., Eds.), American Psychiatric Press, Inc., Washington, DC; 1993; 225-264

Mason, B.J., Frosch, W.A. Secondary Depression. In Treatments of Psychiatric Disorders (Karasu, T.B., Ed.), A Task Force Report of the American Psychiatric Association, American Psychiatric Press, Inc., Washington, DC; 1989

## 19. Other works, publications and abstracts:

Selamoglu, A., Langley, C., Crean, R., Savulich, G., Cormack, F., Sahakian, B., and Mason, B.J. Neuropsychological impairments in young adults with cannabis use disorder, British Association for Psychopharmacology Annual Meeting; London, UK; 2020. (*forthcoming*)

Selamoglu, A., Langley, C., Crean, R., Savulich, G., Cormack, F., Sahakian, B., and Mason, B.J. Impairments in Cognition in Cannabis Dependent Young Adults, Collegium Internationale Neuro-Psychopharmacologicum (CINP) 2019 International Meeting; Athens, Greece; 2019.

Mason, B.J. An evaluation of the Peroxisome proliferator receptor-alpha (PPAR-  $\alpha$ ) agonist, fenofibrate, in a human laboratory model of alcohol use disorder, 17<sup>th</sup> European Society for Biomedical Research on Alcoholism (ESBRA) Congress; Lille, France; 2019.

Frantz, K., Roberto, M., Mason, B.J., Koob, G.F., Volkow, N., and Rodriguez de Fonseca, F. Larry Parsons: Researcher, mentor, and friend, Addiction Biology; 2018; 23:1204-1206.

Mason, B.J., Chesher, N.J., Ribner, J., Lee, J.J. Pharmacological Treatment of Concurrent Cannabis and Alcohol Dependence, NIAAA/NIDA/NCI Enhancing Collaborative Research on Addiction Workshop; Rockville, MD; 2015

Mason, B.J. A human laboratory study of mifepristone treatment for alcohol dependence, Neuropsychopharmacology; 2012; 38:S53

Higley, A.E., Goodell, V., Quello, S., Mason, B.J. Stress and craving: predicting alcohol treatment outcomes using a human laboratory paradigm of interpersonal stress induction, Alcoholism: Clinical and Experimental Research; 2012; 36(s1):101A

Higley, A.E., Crane, N.A., Goodell, V., Spadoni, A.D., Quello, S., Mason, B.J. Craving in response to stress-induction in a human laboratory paradigm predicts treatment outcome in alcohol dependent individuals, Alcoholism: Clinical and Experimental Research; 2011; 35(s1):158A

Mason, B.J., Crean, R., Goodell, V. Precipitated versus natural withdrawal in outpatients with cannabis dependence versus healthy controls, Neuropsychopharmacology; 2010; 35:S55-S56

Perney, P., Mason, B.J., Leher, P. Effect of acamprosate on sleeping disorders during a 24-week follow-up after alcohol withdrawal in a cohort of 592 alcohol-dependent patients, Alcoholism: Clinical and Experimental Research; 2010; 34(s3):169A

Mason, B.J. Human laboratory and clinical trial evidence for gabapentin treatment of alcohol dependence, Alcoholism: Clinical and Experimental Research; 2010; 34(s3):64A

Mason, B.J., Crean, R., Goodell, V, Precipitated versus natural withdrawal in outpatients with cannabis dependence: implications for treatment (2010) 20<sup>th</sup> Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, Page P2-3

Mason, B.J. Subsyndromal disturbances in mood and sleep and relapse prevention in alcohol dependence: results of a randomized controlled trial, Alcoholism: Clinical and Experimental Research; 2010; 34(s2):290A

Spadoni, A.D., Higley, A.E., Goodell, V., Tapert, S.F., Mason, B.J. Cue-reactivity in alcohol dependent volunteers treated with acamprosate, naltrexone, or placebo: fMRI findings in relation to human laboratory results, Alcoholism: Clinical and Experimental Research; 2010; 34(s2):177A

Mason, B., Quello, S., Goodell V. A neuromodulatory approach to subsyndromal disturbances in mood and sleep and relapse prevention in alcohol dependence: results of a randomized controlled trial; The International Journal of Neuropsychopharmacology; 2010; 13(s1)

Mason, B.J. Challenges in comorbidity, Psychiatric Annals; 2008; 38:703-705

Mason, B.J., Lehter, P. Acamprosate efficacy in alcohol-dependent patients: effect of nicotine and illicit substance use on treatment outcomes, Alcoholism: Clinical and Experimental Research; 2008; 32(s1):257A

Mason, B.J., Lehter, P. Women and alcoholism: an individual patient data (IPD) meta-analysis of outcome predictors based on 955 female patients in 15 acamprosate clinical trials, Alcoholism: Clinical and Experimental Research; 2007; 31(s2):58A

O'Malley, S.S., Couper, D., Anton, R., Hosking, J., Johnson, B., Mason, B. Multiple time to event analyses of drinking in the COMBINE study, Alcoholism: Clinical and Experimental Research; 2007; 31(s2):57A

Mason, B.J. Development and validation of human laboratory models for the prediction of medication efficacy in clinical trials, Neuropsychopharmacology; 2005; 30:S41

Mason, B.J., Goodman, A.M. (1997). Brief Intervention and Medication Compliance Procedures Therapist's Manual. Launched on <http://www.alcoholfree.info> in 2004

Mason, B.J., Williams, L.D., Salvato, F.R., Mestre, S., Cutler, R.B. Naltrexone treatment for concurrent tobacco and alcohol dependence, Supplement to Alcoholism: Clinical and Experimental Research; 2004; 28(5):114A

Mason, B. An evidence-based risk assessment of acamprosate and naltrexone in the treatment of alcohol dependence. Proceedings from Campral Symposium – Acamprosate: Setting the Standard in the Treatment of Alcohol Dependence, Rome, Italy; Drugs and Therapy Perspectives; Adis International; 2003; 2(1):22-26

Mason, B.J., Salvato, F.R., Williams, L.D., Cutler, R.B. Naltrexone maintenance treatment of alcohol dependence. Research Society on Alcoholism Annual Meeting, Ft. Lauderdale, FL; Alcoholism:

Clinical and Experimental Research; 2003; 27(s6):147A

Mason, B.J., Goodman, A.M. Acamprosate treatment of alcohol dependence: results of the U.S. multicenter study. Society of Biological Psychiatry Annual Meeting, New Orleans, Louisiana; Biological Psychiatry; 2001; 49(8S):50A

Mason, B.J. Results of the multicenter study of acamprosate in the treatment of alcoholism. Society of Biological Psychiatry Annual Meeting, New Orleans, Louisiana; Biological Psychiatry; 2001; 49(8S):270A

Mason, B.J. Alcohol and depression, relapse and survival: learning to say no. Journal of the California Alliance for the Mentally Ill; 2000; 10(4):84-85

Mason, B.J. Treatment Research section. In Tenth Special Report to the U.S. Congress on Alcohol and Health. Secretary of Health and Human Services, 2000; 451-461

Davidson, J.R.T., Koenke, K., Lerner, J.P., Mason, B.J., McCauley, J., McCardell, E.R., McMurray, J., Sheer, M.K., Spitzer, R.L., Stowe, Z.N., Williams, J.B.W., Yonkers, K.A. Primary Care Evaluation of Mental Disorders for Women PRIME.MD.WOMEN: Women's Health Questionnaire; Pfizer Inc.; 1998

Ownby, R.L., Bieniek, S., Penalver, A., Mason, B.J. Alcohol problems among older adult emergency room patients. Research Society on Alcoholism Annual Meeting, Washington, DC; Alcoholism: Clinical and Experimental Research; 1996; 488A, 20(2):85A

Ownby, R.L., Mason, B.J. Autorhythmicity in hippocampal CA3 neurons: effect on chronic ethanol. Research Society on Alcoholism Annual Meeting, Washington, DC; Alcoholism: Clinical and Experimental Research Supplement; 1996; 285A, 20(2):51A

Ownby, R.L., Mason, B.J. Neural mechanisms underlying alcohol's reinforcing properties. Research Society on Alcoholism Annual Meeting, Washington, DC; Alcoholism: Clinical and Experimental Research Supplement; 1996; 344A, 20(2):61A

Mason, B.J., Goldberg, G., Ritvo, E.C., Salvato, F.R. Nalmefene as a primary treatment versus as an adjunctive treatment for alcoholism: a preliminary study. Research Society on Alcoholism Annual Meeting, Steamboat Springs, CO; Alcoholism: Clinical and Experimental Research Supplement; 1995; 78A, 19(2):16A

Salvato, F.R., Mason, B.J., Williams, L.D. Sertraline treatment of depression concomitant with nalmefene treatment of alcoholism: a case study. Research Society on Alcoholism Annual Meeting, Steamboat Springs, CO; Alcoholism: Clinical and Experimental Research Supplement; 1995; 79A, 19(2):17A

Mason, B.J., Kocsis, J.H. Desipramine in the treatment of depressed alcoholics. American Journal of Psychiatry; 1994; 151:1248

Mason, B.J., Ritvo, E.C., Salvato, F.R., Goldberg, G. Preliminary dose finding studies for nalmefene treatment of alcoholism. Research Society on Alcoholism Annual Meeting, Maui, Hawaii; Alcoholism: Clinical and Experimental Research; 1994; 270A, 18(2):464

Salvato, F.R., Mason, B.J. Changes in transaminases over the course of a 12-week double-blind nalmefene trial in a 38-year old female subject. Research Society on Alcoholism Annual Meeting, Maui, Hawaii; Alcoholism: Clinical and Experimental Research; 1994; 271A, 18(2):465

Mason, B.J., Goldberg, G., Ritvo, E.C., Salvato, F.R., Morgan, R.O. Preliminary comparison of pharmacotherapy as a primary treatment versus as an adjunctive treatment for alcoholism. Seventh Congress of the International Society for Biomedical Research on Alcoholism, Gold Coast, Australia; Alcoholism: Clinical and Experimental Research; 1994; 910A, 18(2):44A

Mason, B.J., Kocsis, J.H. Treatment needs of psychiatrically ill alcoholics. Research Society on Alcoholism Annual Meeting, Toronto, Canada; Alcoholism: Clinical and Experimental Research; 1990; 314A, 14(2):316

Mason, B.J., Kocsis, J.H. Desipramine treatment of secondary depression in alcoholism. Research Society on Alcoholism Annual Meeting, Beaver Creek, CO; Abstract published in Alcoholism: Clinical and Experimental Research; 1989; 283A, 13(2):350

## **20. Patents:**

U.S. Patent No. 5,0852,032, "Method of Treating Nicotine Dependence," issued December, 1998

U.S. Publication No. 2010/0280118, "Methods for Treating Substance Dependence," filed October, 2007

U.S. Publication No. 2010/0249138, "MPZP: A Small Molecule Corticotropin-Releasing Factor Type 1 Receptor (CRF1) Antagonist," filed September, 2007

## **V. PROFESSIONAL:**

### **21. Funded Research:**

Principal Investigator/Executive Director, CNS Effects of Alcohol: Cellular Neurobiology, P60 AA006420, NIAAA; 2017-2022, Principal Investigator, Administrative Core and Clinical Research Component (\$10,833,854 total including indirect)

Principal Investigator, Proof-of-Concept Human Laboratory Testing of Novel Drug Candidates Identified by INIA-NeuroImmune, U01AA025476, NIAAA; 2017-2022 (\$2,615,709 total including indirect)

Principal Investigator, Administrative Supplement to Medication Development for Protracted Abstinence in Alcoholism, R01 AA012602-15S2, NIAAA; 2016-2017 (awarded amount included in parent grant below)

Principal Investigator, Administrative Supplement to Medication Development for Protracted Abstinence in Alcoholism, R01 AA012602-15S1, NIAAA; 2015-2017 (awarded amount included in parent grant below)

Principal Investigator, Glucocorticoid Antagonist Treatment of Alcohol Use Disorder, R01 AA023152, NIAAA; 2014-2019 (\$3,164,165 total including indirect)

Principal Investigator, 2-Year Competitive Collaborative Research on Addiction at NIH (CRAN) Supplement to Pharmacological Treatment of Cannabis Withdrawal and Dependence, R01 DA030988-04S1, NIDA; 2014-2016 (awarded amount included in parent grant below)

Principal Investigator, Pharmacological Treatment of Cannabis Withdrawal and Dependence, R01 DA030988, NIDA; 2010-2015 (\$3,134,041 total including indirect)

Principal Investigator, Gabapentin Treatment of Cannabis Dependence, R01 DA026758, NIDA; 2009-2016 (\$3,323,026 total including indirect)

Principal Investigator, Duloxetine versus Pregabalin for Treatment of Alcohol Dependence, R37 AA014028, NIAAA; 2008-2014 (\$2,853,314 total including indirect)

Program Director, Translational Center on the Clinical Neurobiology of Cannabis Addiction, P20 DA024194, NIDA; 2007-2012 (\$3,831,000 total including indirect)

- Principal Investigator, *Administrative and Scientific Support Core*
- Principal Investigator, *Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults*

Principal Investigator, Gabapentin for Cannabis Withdrawal and Use, R21 DA020766, NIDA; 2006-2008 (\$504,486 total including indirect)

Principal Investigator, Gabapentin Treatment of Alcohol Dependence, R37 AA014028, NIAAA; 2003-2008 (\$3,236,945 total including indirect)

Principal Investigator, A Phase III, Multi-Center, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Medisorb® Naltrexone in Alcohol Dependent Adults, Alkermes, Inc.; 2002-2003

Principal Investigator, Safety and Efficacy of Naltrel in Treatment of Alcohol Dependence, DrugAbuse Sciences, Inc.; 2001-2002

Principal Investigator, Medication Development for Protracted Abstinence in Alcoholism, R01 AA012602, NIAAA; 1999-2017 (\$10,943,806 total including indirect)

Principal Investigator, Behavioral/Pharmacologic Treatment of Alcoholism, U10 AA011727, NIAAA; 1997-2008 (\$1,979,000 total including indirect)

Overall Principal Investigator for 21-site multicenter trial, Acamprosate in Patients with Alcohol Dependence: A Double-Blind, Placebo-Controlled Safety and Efficacy Study at Two Active Dose Levels, Lipha Pharmaceuticals; 1997-1999

**Note: Dr. Mason wrote the research protocol and behavioral therapy manual for this study that was submitted in support of an NDA for a new pharmacotherapy for alcoholism.**



Principal Investigator, Naltrexone in Nicotine and Alcohol Dependence, R01 AA011210, NIAAA; 1996-2005 (\$1,970,925 total including indirect)

Minority Investigator Supplement to NIAAA grant number R01 AA011210 for Lauren D. Williams, M.D.; 1996-2000 (\$290,617 total including indirect)

Principal Investigator, A Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Depression and a DSM-IV Diagnosis of Alcohol Dependence, Pfizer Pharmaceuticals; 1996-1998

Principal Investigator, Nalmefene Maintenance Treatment of Alcoholism, R01 AA10518, NIAAA; 1995-2000 (\$2,116,092 total including indirect)

Minority Investigator Supplement to NIAAA grant number R01 AA10518 for Fernando R. Salvato, M.D.; 1995-1997 (\$102,000 total)

Minority Investigator Supplement to NIAAA grant number R01 AA09560 for Emilio Mantero-Atienza, M.D.; 1993-1995 (\$153,000 total including indirect)

Principal Investigator, Ritanserin in the Treatment of Alcohol Dependence: Double-Blind, Placebo-Controlled Phase II Study, Janssen Research Foundation; 1993-1995

Principal Investigator, An Open Label Usage Study of Trexan as Adjunctive Treatment with Psychosocial Therapy for Individuals with Alcoholism, Dupont Merck Pharmaceutical Company; 1993-1994

Principal Investigator, Nalmefene Modification of Alcoholism, R01 AA09560, NIAAA; 1992-1995 (\$709,091 total including indirect)

Minority Investigator Supplement to NIAAA grant number R01 AA09560 for Fernando R. Salvato, M.D.; 1992-1995 (\$213,997 total including indirect)

Principal Investigator, Desipramine Metabolism in Recovering Alcoholics, R01 AA08111, NIAAA; 1991-1996 (Funding amount not available)

Principal Investigator, Desipramine Treatment of Alcoholism, FIRST Award R01 AA06866, NIAAA; 1986-1991 (Funding amount not available)

## **22. Editorial responsibilities:**

Member, Editorial Board, Journal of Drug and Alcohol Research; 2012-present

Guest Editor, Special issue: human laboratory approaches to addiction research, Addiction Biology; 2009

Guest Editor, Special issue on challenges in comorbidity, Psychiatric Annals; 2008

Member, Editorial Board, Journal of Addiction Medicine, Official Journal of the American Society of Addiction Medicine (ASAM); 2006-present

Field Editor, Editorial Board, Neuropsychopharmacology, Official Publication of the American College of Neuropsychopharmacology (ACNP); 2002-2006

Member, Editorial Board, Alcoholism: Clinical and Experimental Research; 1999-2001

Member, Editorial Board, Journal of Substance Abuse; 1998

Guest Editor, Supplement to Alcoholism: Clinical and Experimental Research; October 1996

Associate Editor, Alcoholism: Clinical and Experimental Research; 1995-1998

Member, Editorial Board, Ninth and Tenth Special Reports to the U.S. Congress on Alcohol and Health from the Secretary of Health and Human Services; 1994-1996

Expert Field Reviewer of Draft Treatment Improvement Protocols (TIP's); Center for Substance Abuse Treatment (CSAT), Department of Health and Human Services; 1994-2007

**Reviewer:**

*Addiction (formerly The British Journal of the Addictions)*

*Addiction Biology*

*Adis International Limited*

*Alcohol and Alcoholism*

*Alcoholism: Clinical and Experimental Research*

*Alcohol Research & Health (formerly Alcohol Health & Research World)*

*American Journal of Psychiatry*

*JAMA-Psychiatry (formerly Archives of General Psychiatry)*

*JAMA-Internal Medicine (formerly Archives of Internal Medicine)*

*Biological Psychiatry*

*Bipolar Disorders*

*CNS Drugs*

*European Neuropsychopharmacology*

*Expert Opinion on Pharmacotherapy*

*International Journal of Neuropsychopharmacology*

*Journal of Addiction Medicine*

*Journal of Clinical Psychiatry*

*Journal of Personality Assessment*

*Journal of Psychiatric Research*

*Journal of Psychopharmacology*

*Journal of Studies on Alcohol*

*Neuropsychopharmacology*

*Pharmacology Biochemistry and Behavior*

*PLOS ONE*

*Progress in Neuro-Psychopharmacology & Biological Psychiatry*

*Psychopharmacology*

**23. Professional and Honorary Organizations:**

College on Problems of Drug Dependence (CPDD)

Collegium Internationale Neuro-Psychopharmacologicum (CINP)

European Society for Biomedical Research on Alcoholism (ESBRA)

American College of Neuropsychopharmacology (ACNP)

International Society for Biomedical Research on Alcoholism (ISBRA)

Research Society on Alcoholism (RSA)

Society for Neuroscience (SFN)

**24. Honors and Awards:**

Smithers Distinguished Scientist Award; American Society of Addiction Medicine; 2017

Path to Recovery Hero; Parents for Addiction Treatment and Healing; State of California Senate Recognition; 2009

Weill Cornell Alumni Award; 2009

The Pearson Family Chair; an endowed chair in alcoholism and addiction research at The Scripps Research Institute; 2007-present

Elected Fellow; American College of Neuropsychopharmacology; 2005

MERIT Award for Medication Development; National Institutes of Health (NIH); 2003

Dean's Senior Clinical Research Award; Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine; 1999-2000

Teacher-Scientist Award; Andrew W. Mellon Foundation, Cornell University Medical College; 1989-1991

**25. Other Professional Activities: Presentations at Professional Meetings**

Human Lab Study of Apremilast for AUD and Future Directions; Integrative Neuroscience Initiative on Alcoholism (INIA) Satellite Meeting at Research Society on Alcoholism (RSA) 42<sup>nd</sup> Annual Scientific Meeting; Minneapolis, MN; 2019

Translational Science of Alcoholism: The Devil is in the Details; UCLA Luskin Thought Leadership Meeting on Translational Science of Alcoholism; Los Angeles, CA; 2019

Treatment of Alcohol Use Disorder: Current Status and Future Directions for AUD Medications; Veterans Administration San Diego Healthcare System/University of California San Diego (VASDHS/UCSD) Substance Use Disorders Seminar; La Jolla, CA; 2019

An Evaluation of the Peroxisome Proliferator-Activated Receptor-Alpha Subtype Agonist, Fenofibrate, in a Human Lab Model of AUD; 17th European Society for Biomedical Research on Alcoholism Congress; Lille, France; 2019

Medication Assisted Treatment for Alcohol Use Disorder: Current Status and Future Directions, University of Alaska Fairbanks Student Affairs Alcohol Misuse meeting, Fairbanks, AK, 2018

Taking Research Findings to the Clinic; Cold Spring Harbor Laboratory course, Cellular Biology of Addiction; Cambridge, UK; 2018

A Human Laboratory Model for Medications Development for Alcohol Use Disorder; Institut de Neurosciences de la Timone; Marseille, France; 2018

Psychopharmacology of addiction; XXV National Congress of the Asociación Psiquiátrica Mexicana (APA); Mérida, Yucatán, México; 2017

Advances in Medication Development for Alcohol Use Disorder; Stellenbosch University Fetal Alcohol Syndrome Epidemiological Research-South Africa (FASER-SA) Clinics and Case Conference Visit; Cape Town, South Africa; 2017

What Medications Are Used to Treat Alcohol Use Disorder?; 40<sup>th</sup> Annual Research Society on Alcoholism (RSA) Scientific Meeting; Denver, CO; 2017

A Human Laboratory Study of Mifepristone as a Novel Treatment for Alcohol Use Disorder; American Psychiatric Association (APA) 2017 Annual Meeting; San Diego, CA; 2017

A Human Laboratory Study of Mifepristone as a Novel Treatment for Alcohol Use Disorder; Alcoholism and Stress: A Framework for Future Treatment Strategies Conference; Volterra, Italy; 2017

Off-label Pharmacological Approaches to AUD – What’s Hot and What’s Not?; American Society of Addiction Medicine (ASAM) 48<sup>th</sup> Annual Conference; New Orleans, LA; 2017

Gabapentin as a Novel Treatment for Alcohol Use Disorder; National Institute of Neurological Disorders and Stroke/National Institute of Mental Health (NINDS/NIMH) Clinical Neuroscience Grand Rounds; Rockville, MD; 2017

The Dark Side of Addiction: Neurocircuitry, Molecular-epigenetic and Clinical-translational Insights; American Neurological Association Spring Brain Conference; Sedona, AZ; 2017

Targeting Relapse-related Symptoms of Insomnia, Dysphoria, and Craving for the Treatment of Alcohol and Cannabis Dependence; National Institute on Drug Abuse-National Institute on Alcohol and Alcoholism (NIDA-NIAAA) “Frontiers in Addiction Research” Mini-Convention; San Diego, CA; 2016

Novel Pharmacological Targets for Treating Alcohol Use Disorder; American Society of Addiction Medicine (ASAM) State of the Art Course in Addiction Medicine; Washington, DC; 2016

The Dark Side of Alcoholism: Implications for Treatment; The Scripps Research Institute (TSRI) Lightning Talks; La Jolla, CA; 2016

Pharmacological Treatment of Cannabis Use Disorder and Withdrawal; University of California, San Diego Clinical and Translational Research Institute (UCSD-CTRI) “Cannabis Across the Life Course” Symposium; La Jolla, CA; 2016

Craving as a Clinical Trial Endpoint of Therapeutics for Cannabis Use Disorders: Feasibility, Pros and Cons; National Institute on Drug Abuse (NIDA) Cannabis Use Disorders Meeting; Rockville, MD; 2016

From Medication Development to Market Introduction; Symposium – International Society of Biomedical Research on Alcoholism and European Society for Biomedical Research on Alcoholism (ISBRA-ESBRA) World Congress on Alcohol and Alcoholism; Berlin, Germany; 2016

Human Laboratory Studies and Medication Development; Cold Spring Harbor Laboratory course, Cellular Biology of Addiction; Cambridge, UK; 2016

Alcohol Use Disorders; American Society for Clinical Psychopharmacology (ASCP) Annual Meeting; Scottsdale, AZ; 2016

Existing and Future Drugs in Addiction Medicine; Addictions: à La Croisée de la Recherche et de la Clinique Conference; Bordeaux, France; 2016

Clinical Validation of the Stress Response as a Pharmacological Target for Treating Alcohol Dependence; Gordon Research Conference on Alcohol and the Nervous System; Galveston, TX; 2016

A Translational Approach to Medication Development for Alcohol Dependence; Seminar at the Center for Substance Abuse Research, Temple University; Philadelphia, PA; 2015

Evidence for Gabapentin Treatment for Alcohol and/or Cannabis Dependence; International Society of Addiction Medicine (ISAM) Conference; Edinburgh, Scotland, UK; 2015

A Proof-of-Concept Human Laboratory Study of Glucocorticoid Receptor Antagonism as a Novel Treatment for Alcohol Dependence; Australasian Winter Conference on Brain Research (AWCBR); Queenstown, New Zealand; 2015

Translational Research: Prospects for the Treatment of Alcohol Misuse; 4<sup>th</sup> Asia-Pacific Society for Alcohol and Addiction Research (APSAAR)/5<sup>th</sup> International Drug Abuse Research Society (IDARS) Conference; Sydney, Australia; 2015

Are There Medications to Treat Dual Disorders?; 9<sup>th</sup> ALBATROS International Congress of Addictology[sic]; Paris, France; 2015

Alcohol Dependence and its Comorbidity with Major Depression and Sub-Clinical Depressive Symptoms; Anxiety and Depression Association of America (ADAA) Anxiety and Depression Conference; Miami, FL; 2015

Innovative Pharmacological Strategies to Treat Alcohol Use Disorder; 168<sup>th</sup> American Psychiatric Association (APA) Annual Meeting, Toronto, Ontario, Canada; 2015

Identifying Potential Clinical Predictors of Acamprosate Response with a Human Laboratory Model of Protracted Withdrawal; 38<sup>th</sup> Annual Research Society on Alcoholism (RSA) Scientific Meeting; San Antonio, TX; 2015

Personalized Treatment with Acamprosate: Novel Paradigms to Optimize Clinical Response; Symposium—38<sup>th</sup> Annual Research Society on Alcoholism (RSA) Scientific Meeting; San Antonio, TX; 2015

The Predictive Validity of a Human Laboratory Model for Clinical Trial Outcomes in Alcohol Use Disorder; Invited Speaker—University of Puerto Rico; San Juan, PR; April 2015

Clinical Validation of Central Stress Systems as a Pharmacological Target in Treating Alcoholism; Seminar— University of Puerto Rico; San Juan, PR; April 2015

Human Laboratory and Clinical Trial Evidence for Gabapentin Treatment of Alcohol Dependence; Invited Speaker-Mayo Clinic Translational Bridges in Mood & Addiction CME; Rochester, MN; September 2014

The Fight Against Alcoholism; Invited Speaker-The Scripps Research Institute Frontiers in Science Lecture Series; La Jolla, CA; August 2014

Medication Development for the Dark Side of Alcohol and Cannabis Addiction; Invited Speaker-NIDA Intramural Research Program; San Juan, PR; July 2014

Clinical Validation of Central Stress Systems as a Pharmacological Target in Treating Alcoholism: A Randomized Controlled Trial of Gabapentin; Invited Speaker-Research Society on Alcoholism 37<sup>th</sup> Scientific Meeting and 17<sup>th</sup> Congress of ISBRA; Bellevue, WA; June 2014

Pharmacological Treatment of Cannabis Dependence; Invited Speaker-NIDA International Forum; San Juan, PR; June 2014

A Glucocorticoid Antagonist Shows Therapeutic Potential for Alcohol Dependence in a POC Human Lab Study; Invited Speaker-3<sup>rd</sup> International Congress on Alcoholism and Stress; Volterra, Italy; May 2014

Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial; Invited Speaker-Scripps Clinic/Scripps Green Hospital Grand Rounds; La Jolla, CA; March 2014

Gabapentin as a Novel Treatment for Alcohol Dependence, Plenary Lecture-Society on NeuroImmune Pharmacology 20<sup>th</sup> Scientific Conference; New Orleans, LA; March 2014

Gabapentin as a Novel Treatment for Alcohol and Cannabis Dependence; Guest Speaker- George Washington University; Washington DC; October 2013

Gabapentin as a Novel Treatment for Alcohol and Cannabis Dependence; Guest Speaker- Centre Hospitalier Universitaire Vaudois (CHUV); Lausanne, Switzerland; September 2013

Predictive Validity of Human Laboratory Models for Medication Development in Alcohol Dependence; Invited Speaker- Cold Spring Harbor Laboratory course, Cellular Biology of Addiction; Cold Spring Harbor, NY; August 2013

Predictive Validity of Human Laboratory Models for Medication Development in Alcohol Dependence; Guest Speaker – University of California, Los Angeles, CA; June 2013

Can We Treat Cannabis Dependence?; Invited Speaker – ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe; Nice, France; March 2013

Translating the Neurobiology of Addiction into New Treatments: Medication Assisted Recovery; RiverMend Health Scientific Advisory Board Meeting; Malibu, CA; 2013

A Human Laboratory Study of Mifepristone Treatment for Alcohol Dependence; Symposium – International Drug Abuse Research Society (IDARS) Satellite Meeting; Mexico City, Mexico; 2013

Gabapentin: Treatment for the Dark Side of Dependence; Invited Speaker – Summer Course: Cellular Biology of Addiction – Cold Spring Harbor Laboratory; Barcelona Biomedical Research Park, Barcelona, Spain; July 2012

Gabapentin Treatment of Alcohol Dependence and Alcohol-Related Disturbances in Mood and Sleep; Symposium – American Academy of Addiction Psychiatry (AAAP) Meeting; Aventura, FL; 2012

A Human Laboratory Study of Mifepristone Treatment For Alcohol Dependence; Symposium – American College of Neuropsychopharmacology (ACNP) Meeting; Hollywood, FL; 2012

Predictive Validity of a Human Laboratory Model for Medication Development in Alcohol Dependence; Symposium – International Society for Biomedical Research on Alcoholism (ISBRA) Meeting; Sapporo, Japan; 2012

Translating Research into Practice, Gabapentin Treatment of Alcohol and Cannabis Dependence; American Psychiatric Association (APA) Pipeline Summit. Arlington, CA; 2012

Novel Pharmacological Approaches to Cannabis Dependence; Guest Speaker – Addiction Research Seminar Series – University of California, San Diego; San Diego, CA; January 2012

Predictive Validity of Human Laboratory Models for Medication Development in Alcohol Dependence; Symposium – International Drug Abuse Research Society (IDARS) Meeting; Istanbul, Turkey; 2011

Novel Pharmacological Approaches to Cannabis Dependence and Withdrawal; Grand Rounds – Department of Psychiatry and Behavioral Sciences – Miller School of Medicine University of Miami; Miami, FL; April 2011

Mental Health, Neuroscience and the Wellbeing of Society: Substance Abuse; Panel – British Association for Psychopharmacology (BAP) Meeting; Harrogate, UK; 2011

Medication Development for Cannabis Dependence and Withdrawal; Invited Speaker – University of Camerino School of Pharmacy; Rome; October 2010

Human Laboratory Models of Craving; Invited Speaker – The Institute of Neurosciences; Bordeaux; October 2010

An Evidence-Based Clinician's Guide to the New Pharmacotherapies for Alcoholism; Invited Speaker – Alcohol Community Seminar for the Los Angeles Department of Public Health; Alhambra, CA; October 2010

Evaluation of Craving and Sleep in a Human Laboratory Study of Acamprosate, Naltrexone and Placebo in Alcohol Dependent Volunteers; Merck Serono Symposium – Acamprosate : From Research on Neuroprotection to Clinical Evidence; Paris, France; 2010

Pharmacotherapies for Cannabis Dependence; Invited Speaker – National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) Seminar Series; Baltimore, MD; March 2010

Precipitated Versus Natural Withdrawal in Cannabis Dependent Volunteers Relative to Non MJ-Using Controls; Symposium – American College of Neuropsychopharmacology (ACNP) Meeting; Miami Beach, FL; 2010

Human Laboratory and Clinical Trial Evidence for Gabapentin Treatment of Alcohol Dependence; Symposium – International Society for Biomedical Research on Alcoholism (ISBRA) Meeting; Paris, France; 2010

Novel Neurobiological Targets for the Treatment of Alcoholism, International Drug Abuse Research Society (IDARS) Annual Meeting; Rio de Janeiro, Brazil; 2010

Precipitated Versus Natural Withdrawal in Outpatients with Cannabis Dependence: Implications for Treatment; International Cannabinoid Research Society (ICRS) Annual Meeting; Lund, Sweden; 2010

Gabapentin in Alcoholism: From Laboratory Study to Clinical Trial; Symposium – World Congress of Basic and Clinical Pharmacology; Copenhagen, Denmark; 2010

Subsyndromal Disturbances in Mood and Sleep and Relapse Prevention in Alcohol Dependence: Results of a Randomized Controlled Trial; Symposium – Research Society on Alcoholism (RSA) Annual Meeting; San Antonio, TX; 2010

Gabapentin Treatment of Subsyndromal Disturbances in Mood in Alcohol Dependence; Symposium – New Research Approaches for Mental Health Interventions (NCDEU) Annual Meeting; Boca Raton, FL; 2010

Dangerous Health Effects of Alcohol: What Your Patients and Clients Need to Know, County of Los Angeles Public Health Substance Abuse Prevention and Control Lecture, 2010



Effects of Gabapentin on Cannabis Withdrawal and Dependence; California Society of Addiction Medicine (CSAM) State of the Art 2009; San Francisco, CA; 2009

Human Laboratory and Clinical Trial Evidence for a Neuromodulatory Approach to Treatment of Alcohol Dependence; International Drug Abuse Research Society (IDARS) Annual Meeting; Seoul, South Korea; 2009

Future Treatment Prospects; Invited Speaker – ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe; Nice, France; March 2009

A Double-Blind, Placebo-Controlled Study of Gabapentin Treatment of Cannabis Dependence; Late-Breaking News Report – New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Hollywood, FL; 2009

Guest Presenter to the Alcohol and Drug Program Administration, County of Los Angeles Department of Public Health, 2009

Effects of Acamprosate in The COMBINE Study: A Cell x Cell Comparison; Symposium – Research Society on Alcoholism (RSA) Annual Meeting; San Diego, CA; 2009

Human Laboratory and Clinical Trial Evidence for Gabapentin Treatment of Alcohol Dependence; Symposium – American Psychiatric Association (APA) Annual Meeting; San Francisco, CA; 2009

Effect of Patient Involvement on Treatment Outcomes and Acamprosate Efficacy in Alcohol-Dependent Patients; American Academy of Addiction Psychiatry (AAAP) Annual Meeting; Boca Raton, FL; 2008

A Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence: Predicting Medication Efficacy; Symposium – Collegium Internationale Neuro-Psychopharmacologicum (CINP) Annual Meeting; Munich, Germany; 2008

Gabapentin for the Treatment of Cannabis-Related Disorders; Late-Breaking Research – The College on Problems of Drug Dependence (CPDD) Annual Meeting; San Juan, PR; 2008

Effect of Nicotine and Illicit Substance Use on Treatment Outcomes: Acamprosate Efficacy in Alcohol-Dependent Patients; American Society of Addiction Medicine (ASAM) Annual Meeting; Toronto, Canada; 2008

The Clinical Relevance of Clinical Trials for the Treatment of Alcohol Dependence; Grand Rounds – Department of Psychiatry and Psychology – Mayo Clinic College of Medicine; Rochester, MN; April 2008

Individual Patient Data Meta-Analysis of Predictors of Outcome across USA and European Acamprosate Randomized Clinical Trials in Alcohol Dependence; Invited Speaker – Institute of Psychiatry; London; February 2008

A Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence: Predicting Medication Efficacy; Symposium – American College of Neuropsychopharmacology (ACNP) Annual Meeting; Boca Raton, FL; 2007

Psychiatric Antecedents and Subsyndromal Anxiety in Patients with Alcohol Dependence: Effects of Acamprosate; American Academy of Addiction Psychiatry (AAAP) Annual Meeting; Coronado, CA; 2007

The Clinical Relevance of Clinical Trials for the Treatment of Alcohol Dependence; California Society of Addiction Medicine (CSAM) State of the Art 2007; Universal City, CA; 2007

Women and Alcoholism: An Individual Patient Data (IPD) Meta-Analysis of Outcome Predictors Based on 955 Female Patients in 15 Acamprosate Clinical Trials; American Society of Addiction Medicine (ASAM) Annual Meeting; Miami, FL; 2007

A Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence: Implications for Predicting Medication Efficacy; NIAAA / INSERM Meeting; Paris, France; 2007

Alcohol Use Disorders: The Diagnostic Conundrum – Gender/Sex Issues; Symposium – International Society for Biomedical Research on Alcoholism (ISBRA) Satellite Meeting; Newport, Australia; 2006

Background and Rationale for the COMBINE Study; Symposium – International Society for Biomedical Research on Alcoholism (ISBRA) World Congress; Sydney, Australia; 2006

Using Acamprosate in the USA; Symposium – International Society for Biomedical Research on Alcoholism (ISBRA) World Congress; Sydney, Australia; 2006

Development of a Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence: Implications for Predicting Medication Efficacy in Clinical Trials; Symposium – Collegium Internationale Neuro-Psychopharmacologicum (CINP) Annual Meeting; Chicago, IL; 2006

Development of a Human Laboratory Model of Risk Factors for Relapse in Alcohol Dependence: Implications for Predicting Medication Efficacy in Clinical Trials; Symposium – American Psychiatric Association (APA) Annual Meeting; Toronto, Canada; 2006

Development of Human Laboratory Models of Protracted Abstinence for the Prediction of Medication Efficacy; Symposium – American Society of Addiction Medicine (ASAM) Annual Meeting; San Diego, CA; 2006

Naltrexone and Nicotrol for Concurrent Tobacco and Alcohol Dependence; Symposium – Pharmacology, Biochemistry & Behavior Conference Annual Meeting; Morzine, France; 2006

An Evidence-Based Clinician's Guide to the New Pharmacotherapies for Alcoholism; Invited Speaker – Frontiers of Science Lecture at American Psychiatric Association (APA) Annual Meeting; Toronto, Canada; May 2006

A Clinical Guide to the New Pharmacotherapies for Alcohol Dependence: An Evidence-Based Risk-Benefit Assessment; William K. Warren Jr. Frontiers in Neuroscience Conference; Tulsa, OK; February 2006

A Risk-Benefit Comparison of Acamprosate and Naltrexone Treatment of Alcohol Dependence; Grand Rounds – Kalispell Regional Medical Center; Kalispell, MT; November 2005

New Pharmacotherapies for the Treatment of Alcoholism; Addiction to Psychotropic Drugs Conference – Menendez Pelayo International University of Barcelona; Barcelona, Spain; July 2005

Acamprosate and Naltrexone Treatment for Alcohol Dependence: An Evidence-Based Risk Benefit Assessment; Grand Rounds – Payne Whitney Clinic – Cornell Medical Center; New York, NY; March 2005

Acamprosate and Naltrexone Treatment for Alcohol Dependence: An Evidence-Based Risk Benefit Assessment; Grand Rounds – Stanford University School of Medicine; San Francisco, CA; February 2005

Development and Validation of Human Laboratory Models for the Prediction of Medication Efficacy in Clinical Trials; Symposium – American College of Neuropsychopharmacology (ACNP) Annual Meeting; Waikoloa, HI; 2005

Individual Patient Data Meta-Analysis of Predictors of Outcome Including U.S. and European Acamprosate Studies; Symposium – Research Society on Alcoholism (RSA) Annual Meeting; Santa Barbara, CA; 2005

Naltrexone and Nicotrol for Concurrent Tobacco and Alcohol Dependence; Symposium – Research Society on Alcoholism (RSA) Annual Meeting; Santa Barbara, CA; 2005

Alcohol Dependence: Translational and Treatment Research; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 2005

Chair; NIMH Update Session; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 2005

Acamprosate and Naltrexone Treatment for Alcohol Dependence: An Evidence-Based Risk-Benefit Assessment; American Psychiatric Association (APA) Annual Meeting; Atlanta, GA; 2005

Chair; Naltrexone, Pharmacological Aspects and Therapeutic Applications; International Society of Addiction Medicine (ISAM) Annual Meeting; Mar del Plata, Argentina; 2005

Mechanisms of Drinking: Implication for Pharmacotherapy; International Society of Addiction Medicine (ISAM) Annual Meeting; Mar de Plata, Argentina; 2005

Implementing Pharmacotherapy for Alcohol Use Disorders: Focus on Acamprosate; American Society of Addiction Medicine (ASAM) Annual Meeting; Dallas, TX; 2005

Acamprosate and Naltrexone Treatment for Alcohol Dependence: An Evidence-Based Risk-Benefit Assessment; American Pharmacists Association (APhA); Orlando, FL; 2005

Medication Development for Alcoholism; National Institute on Alcohol Abuse and Alcoholism; Washington, D.C.; November 2004

Acamprosate Response in Clinical Sub-Types of Alcohol Dependence: A Review of the Integrated Summary of Efficacy; American Academy of Addiction Psychiatry (AAAP); San Juan, PR; 2004

Acamprosate Treatment for Alcohol Dependence with and without Comorbid Substance Abuse; Collegium Internationale Neuro-Psychopharmacologicum (CINP); Brno, Czech Republic; 2004

Naltrexone Maintenance Treatment of Alcohol Dependence; Collegium International Neuro-Psychopharmacologicum (CINP) Annual Meeting; Paris, France; 2004

Substance Abuse and the Path to Recovery: Neuropharmacology; Scripps McDonald Center; San Diego, CA; May 2004

Acamprosate and Naltrexone Treatment for Alcohol Dependence: An Evidence-Based Risk-Benefit Assessment; Grand Rounds – University of California, San Diego; San Diego, CA; March 2004

Alcohol Pharmacotherapies and Treatment of Comorbidity; The Australian Professional Society on Alcohol and Other Drugs (APSAD) Conference; Brisbane, Australia; 2003

Naltrexone Treatment for Concurrent Tobacco and Alcohol Dependence; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 2003

Treatment of Alcoholism; 9<sup>th</sup> Annual Santa Fe Psychiatric Symposium; Santa Fe, NM; 2003

Naltrexone Maintenance Treatment of Alcohol Dependence; Research Society on Alcoholism (RSA) Annual Meeting; Fort Lauderdale, FL; 2003

Advanced Treatment of Alcohol and Nicotine Addiction: An Evidence-Based Risk-Benefit Assessment; 4<sup>th</sup> European College of Neuropsychopharmacology (ECNP) Workshop; Nice, France; 2003

Naltrexone Maintenance Treatment of Alcohol Dependence; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 2002

An Evidence-Based Risk-Benefit Assessment of Acamprosate and Naltrexone for Alcohol Dependence; Campral International Symposium; Rome, Italy; 2002

Medication Development for Protracted Abstinence and Relapse to Alcoholism: New Approaches and New Candidates: Novel Clinical Approaches for Developing Medications for Protracted Abstinence and Relapse; Symposium-Research Society on Alcoholism (RSA) Annual Meeting; San Francisco, CA; 2002

Chair; Basic Science to Clinical Practice - Combination Therapy vs. Monotherapy in Comorbid Depression and Alcohol Dependence; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 2002

New Pharmacological Treatment Strategies for Alcohol Dependence; 4<sup>th</sup> Annual Masters of Psychiatry Conference; Miami Beach, FL; 2002

Effects of Acamprosate on Alcohol and Drug Use in the American Clinical Study; Campral Satellite Symposium; Trieste, Italy; 2001

Results of the American Clinical Study: Focus on Alcohol Dependence in Women; European Society for Biomedical Research on Alcoholism (ESBRA) Campral Satellite Symposium; Paris, France; 2001

Organizer; Potential Neuroprotective Effects of Acamprosate; Symposium – Research Society on Alcoholism (RSA) Annual Meeting; Montreal, Canada; 2001

The Diagnosis and Treatment of Primary Alcoholism; Symposium – American Psychiatric Association (APA) Annual Meeting; New Orleans, LA; 2001

Glutamate and Alcoholism: Reward, Vulnerability, and Treatment; Symposium - Society of Biological Psychiatry (SOBP) Annual Meeting; New Orleans, LA; 2001

Chair; Acamprosate: New Preclinical and Clinical Research; Symposium – American Society of Addiction Medicine (ASAM) Annual Meeting; Los Angeles, CA; 2001

Acamprosate Treatment of Alcohol Dependence: Results of the U.S. A. Multicenter Study; Hot Topics Session – American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 2000

Integrating American and European Campral Clinical Research Findings; Swedish Association of Research in Alcohol and Drugs Annual Meeting; Gothenburg, Sweden; 2000

Worldwide Benefits of Acamprosate: Efficacy, Safety and Quality of Life - Efficacy and Safety Results of the American Clinical Study; Campral International Symposium; Seville, Spain; 2000

Addressing Addictive Behaviors Through Health and Social Systems - Pharmacotherapy for Alcohol Dependence; Ninth International Conference on Treatment of Addictive Behaviors (ICTAB-9); Cape Town, South Africa; 2000

Acamprosate in the Management of Alcohol Dependence and Relapse Prevention – Review of the Pharmacology and Clinical Potential of Acamprosate in the Management of Alcohol Dependence and Relapse Prevention; Satellite Symposium - Ninth International Conference on Treatment of Addictive Behaviors (ICTAB-9); Cape Town, South Africa; 2000

Pharmacological Relapse Prevention in Alcohol Dependence - Methodology and Behavioral Therapy of the U.S. Acamprosate Study; Symposium – International Society for Biomedical Research on Alcoholism (ISBRA) Congress; Yokohama, Japan; 2000

Organizer; Acamprosate: New Preclinical and Clinical Research – Results of the U.S. Multicenter Study of Acamprosate; Symposium-Research Society on Alcoholism (RSA) Annual Meeting; Denver, CO; 2000

Acamprosate Treatment of Alcohol Dependence; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 2000

Acamprosate Treatment of Alcohol Dependence: Results of the U.S. Clinical Study; Campral International Product Workshop; Lyon, France; 2000

Acamprosate Treatment of Alcohol Dependence; Symposium – American Psychiatric Association (APA) Annual Meeting; Chicago, IL; 2000

Cognitive Effects of Naltrexone and Acamprosate Administered Alone and In Combination; Research Society on Alcoholism (RSA) Annual Meeting; Santa Barbara, CA; 1999

Naltrexone Augmentation of Sertraline in Depressed Alcoholics; American Psychiatric Association (APA) Annual Meeting; Washington, DC; 1999

**Note: Preliminary results from this NIAAA-funded study were selected by the Program Committee of the American Psychiatric Association as a project having high scientific and clinical significance.**

Depression in Nicotine, Alcohol and Cocaine Abuse; Symposium – American Psychiatric Association (APA) Annual Meeting; Washington, DC; 1999

Cognitive Effects of Naltrexone and Acamprosate Administered Alone and In Combination; American College of Neuropsychopharmacology (ACNP) Annual Meeting; Acapulco, Mexico; 1999

Clinical Trials for Depressed Alcoholics; National Institute on Alcohol Abuse and Alcoholism (NIAAA) Symposium - American Society of Addiction Medicine (ASAM) Annual Meeting; New York, NY; 1999

Naltrexone and/or Sertraline in Comorbid Depression and Alcoholism; American College of Neuropsychopharmacology (ACNP) Annual Meeting; Las Croabas, PR; 1998

**Note: This is the first report of the safety and efficacy of this combination treatment for the frequently co-occurring disorders of depression and alcoholism.**

Cross-Cultural Comparisons in Alcohol-Use Disorders: New Avenues for Research; National Institute on Alcohol Abuse and Alcoholism (NIAAA), U.S., and National Institute on Alcoholism, Japan, Workshop; Tokyo, Japan; 1998

Methodology and Demography of the U.S. Multicenter Study of Acamprosate in Alcohol Dependence; 3<sup>rd</sup> Campral Symposium; Lisbon, Portugal; 1998

Naltrexone and/or Sertraline in Outpatients with Alcoholism and Depression; 11<sup>th</sup> European College of Neuropsychopharmacology (ECNP) Congress; Paris, France; 1998

Integrating Pharmacotherapy and Psychosocial Interventions in Alcoholism; Symposium - 9<sup>th</sup> Congress of the Association of European Psychiatrists (AEP); Copenhagen, Denmark; 1998

Chair; Treatment and Research Issues in Comorbid Nicotine and Alcohol Dependence; Symposium - 9<sup>th</sup> Congress of the International Society for Biomedical Research on Alcoholism (ISBRA); Copenhagen, Denmark; 1998

Design Issues in Multicenter Pharmacotherapy Trials for Alcoholism; Symposium - Research Society on Alcoholism (RSA) Annual Meeting; Hilton Head, SC; 1998

Chair; Integration of Pharmacological and Behavioral Treatments in Clinical Trials for the Addictions; Workshop - NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 1998

Current Management of Alcohol and Substance Abuse; Psychopharmacology 1998 Clinical and Research Update - Stanford University School of Medicine; San Francisco, CA; 1998

New Medications to Treat Alcoholism; First Interamerican Medical Conference; Miami Beach, FL; 1998

Management of Depression Secondary to Alcoholism; Grand Rounds - North Shore University Hospital-Cornell University Medical College; Manhasset, NY; November 1997

New Pharmacotherapies for Alcohol Dependence; Grand Rounds - Payne Whitney Clinic-Cornell Medical Center; New York, NY; October 1997

Methodology of the U.S. Multicenter Study of Acamprosate in Alcohol Dependence; American College of Neuropsychopharmacology (ACNP) Annual Meeting; Kamuela, HI; 1997

Nalmefene Modification of Alcoholism; 10<sup>th</sup> European College of Neuropsychopharmacology (ECNP) Congress; Austria, Vienna; 1997

Co-chair and presenter; Developing Clinical Trials in Substance-Dependent Patients with Psychiatric Comorbidity; Workshop - NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 1997

Pharmacotherapies for Alcohol Dependence; Grand Rounds - Stanford University School of Medicine; Stanford, CA; May 1997

New Pharmacotherapies for the Treatment of Alcoholism: Clinical Applications; Grand Rounds - Palo Alto Veterans Administration Medical Center; Palo Alto, CA; May 1997

Management of Depression Secondary to Alcoholism; Symposium - American Psychiatric Association (APA) Annual Meeting; San Diego, CA; 1997

Pharmacotherapy for Comorbid Depression in Alcohol Dependence; Symposium - Research Society on Alcoholism (RSA) Meeting; San Francisco, CA; 1997

Nalmefene Modification of Alcoholism; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 1996

Pharmacotherapy of Alcoholism; Symposium - Research Society on Alcoholism (RSA) Annual Meeting; Washington, DC; 1996

Co-chair and presenter; Methodological Considerations in Smoking Cessation Clinical Trials; Workshop - NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 1996

Presenter at media briefing sponsored by the American Medical Association - Topics: Treatment of Depression and Alcoholism and Women and Alcoholism; Millennium Hotel, New York, NY; March 12, 1996

Chair; Applying New Alcoholism Research to Treatment; Workshop - American Psychiatric Association (APA) Annual Meeting, Miami, FL; 1995

Treating Alcoholism and Comorbidity of Psychopathology; Symposium - American Psychiatric Association (APA) Annual Meeting, Miami Beach, FL; 1995

Medications in Alcoholism Treatment; American Psychiatric Association (APA) Annual Meeting, Miami, FL; 1995

Symptom Substitution in Opiate Antagonist Treatment of Alcoholism; American College of Neuropsychopharmacology (ACNP) Annual Meeting, San Juan, PR; 1995

Preliminary Dose Finding for Nalmefene Treatment of Alcoholism; European College of Neuropsychopharmacology (ECNP) Annual Meeting, Venice, Italy; 1995

New Pharmacotherapies for Addiction: Results of the Multi-center Trials; Symposium - NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Orlando, FL; 1995

Chair; Efficacy of Therapies in Drug and Alcohol Addiction; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Workshop; Orlando, FL; 1995

Pharmacotherapy of Alcoholism: Recent Findings; Symposium - American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami Beach, FL; 1995

Current Health Concerns in Alcoholism; Hemispheric Health Ministers Conference; Miami, FL; 1995

The Rationale for a Pharmacotherapy of Alcoholism; University of Wisconsin-Madison Medical School; Madison, WI; 1995

Pharmacotherapy for Depression Comorbid with Alcoholism; Satellite Video Teleconference: Pharmacotherapy Advances in the Treatment of Alcoholism; Veterans Administration Medical Center; St. Louis, MO; 1995

Pharmacological Therapies for the Treatment of Alcoholism; Presentation in association with Rush-Presbyterian-St. Luke's Medical Center; Chicago, IL; 1995

Maximizing Outcome of Alcoholism Treatment; Presentation in association with Columbia University and the New York State Psychiatric Institute; New York, NY; 1995



Pharmacological Approach to Alcoholism; Presented at the 18th Annual Tennessee School on Alcohol and Other Drug Studies; Vanderbilt University; Nashville, TN; 1995

New Trials of Nalmefene in Alcoholics; Texas Research Society on Alcoholism (RSA) Annual Meeting; Austin, TX; 1995

The Psychologist's Role in Pharmacologic and Behavioral Treatment of Alcoholism; American Psychological Association (APA) Annual Meeting; Los Angeles, CA; 1994

Chair and presenter; Preliminary Dose Finding Studies for Nalmefene Treatment of Alcoholism; Research Society on Alcoholism (RSA) Annual Meeting; Maui, Hawaii; 1994

Preliminary Comparison of Pharmacotherapy as a Primary Treatment versus as an Adjunctive Treatment for Alcoholism; Seventh Congress of the International Society for Biomedical Research on Alcoholism (ISBRA); Gold Coast, Australia; 1994

Methodology Issues for Clinical Treatment Trials in Alcoholism and the Addictions; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: Workshop; Marco Island, FL; 1994

Chair; NIMH Update Session; New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Marco Island, FL; 1994

New Treatments of Alcoholism and Addictive Behaviors; Hemispheric Health Ministers Meeting; Miami, FL; 1994

Depression and Alcoholism in the Elderly; presented at the Substance Abuse and the Older Adult Conference; The Florida Mental Health Institute; University of South Florida; Tampa, FL; 1994

Pharmacotherapy of Alcoholism; Grand Rounds-Department of Family Medicine, University of Miami School of Medicine; Miami, FL; 1994

Emerging Pharmacotherapy in Alcoholism Treatment; Center for Substance Abuse Treatment (CSAT) State Systems Development Program Conference; Seattle, WA; 1994

Nalmefene Modification of Alcohol Dependence: A Pilot Study; American Psychiatric Association (APA) Annual Meeting; San Francisco, CA; 1993

CDRS Predictors of Drug Response in Dysthymia; American Psychiatric Association (APA) Annual Meeting; San Francisco, CA; 1993

Opioid Antagonists: Promising Pharmacotherapy for Alcoholism; Symposium - Research Society on Alcoholism (RSA) Annual Meeting; San Antonio, TX; 1993

Pharmacological Treatment of Depression in Alcoholism; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 1993

Pharmacotherapy of Alcoholism: New Research Findings and Methodologies; Alcoholism Treatment Research and Evaluation Didactic Workshop for Eastern European Alcoholism Researchers; sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA); San Antonio, TX; 1993

Nalmefene Treatment of Alcoholism: Results of a Pilot Study; The Rockefeller University; New York, NY; 1993

New Pharmacological Treatments for Alcoholism; Center on Alcoholism, Substance Abuse and Addictions; University of New Mexico; Albuquerque, NM; 1993

Repeated Measures of Body Weight and Hamilton Depression Scores in Alcoholics Chronically Treated with Nalmefene - A New Opiate Antagonist; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 1992

Pharmacotherapies for Alcoholism: Update; Symposium - Research Society on Alcoholism (RSA) Annual Meeting; San Diego, CA; 1992

Comorbidity and Substance Abuse Treatment; Symposium - American Psychiatric Association (APA) Annual Meeting; Washington, DC; 1992

Desipramine Metabolism in Recovering Alcoholics; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; Boca Raton, FL; 1992

Panelist; Methodologies in Pharmacotherapy: Workshop - Sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA); Rockville, MD; 1992

Longterm Antidepressant Treatment of Alcoholism; American Psychiatric Association (APA) Annual Meeting; New Orleans, LA; 1991

Desipramine Treatment of Alcohol Dependence and Secondary Depression; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 1991

Psychiatric Comorbidity in Methadone Maintained Patients; The College on Problems of Drug Dependence (CPDD) Annual Meeting; Palm Beach, FL; 1991

Longterm Antidepressant Treatment of Alcoholism; Research Society on Alcoholism (RSA) Annual Meeting; Marco Island, FL; 1991

Desipramine Metabolism in Recently Abstinent Alcoholics; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 1990

Treatment Needs of Psychiatrically Ill Alcoholics; Research Society on Alcoholism (RSA) Annual Meeting; Toronto, Canada; 1990

Family History in Alcoholics with Severe Psychiatric Co-morbidity: Genetics and Alcoholism; Recent Advances Symposium; Montreal, Quebec; 1990

Desipramine Treatment of Alcoholism; NIMH New Clinical Drug Evaluation Unit (NCDEU) Annual

Meeting; Key Biscayne, FL; 1990

Treatment Needs of Psychiatrically Ill Alcoholics; American Psychiatric Association (APA) Annual Meeting; New York, NY; 1990

Rorschach Characteristics of Survivors of a Suicide Attempt. XIIIth International Congress of Rorschach and Projective Techniques; Paris, France; 1990

The Cornell Dysthymia Rating Scale; American Psychiatric Association (APA) Annual Meeting; San Francisco, CA; 1989

Desipramine Treatment of Secondary Depression in Alcoholism; Research Society on Alcoholism (RSA) Annual Meeting; Beaver, CO; 1989

Concomitant Psychiatric and Medical Disorder in Alcoholic Inpatients: Research and Treatment Issues; Research Society on Alcoholism (RSA) Annual Meeting; Wild Dunes, SC; 1988

Molindone and Haloperidol: Side Effect Differences; American Psychiatric Association (APA) Annual Meeting; Chicago, IL; 1987

Seizure Threshold, Dose, and ECT Response; American Psychiatric Association (APA) Annual Meeting; Chicago, IL; 1987

Desipramine Blood Level Measurements and Clinical Outcome in Alcoholics; American College of Neuropsychopharmacology (ACNP) Annual Meeting; San Juan, PR; 1987

Cognitive and Perceptual Rorschach Indicators of Depression; American Psychological Association (APA) Annual Meeting; Washington, DC; 1986

Psychological Predictors of Suicide; American Psychiatric Association (APA) Annual Meeting; Washington, DC; 1986

The Relationship of Rorschach Variables to Intelligence; American Psychological Association (APA) Annual Meeting; Los Angeles, CA; 1985

Acute Effects of Electroconvulsive Therapy Upon Heart Rate and Blood Pressure in Depressed Patients: Correlations with Outcome and Repeated Treatment; Society of Biological Psychiatry Annual Meeting; Dallas, TX; 1985

The Fallacy of Studying Suicide Potential after the Attempt; Eastern Psychological Association Annual Meeting; Boston, MA; 1985

A Review of the Suicide Constellation; International Rorschach Congress; Barcelona, Spain; 1984

## **VI. TEACHING:**

### **26. Teaching Awards Received:**

1989-1991 Cornell University Medical College, New York, NY; Andrew W. Mellon Teacher-Scientist Award

**27. Teaching Specialization (*course taught*):**

**University of California, San Diego:**

- 2017 A Translational Approach to Medication Development for Alcohol Use Disorder; NIAAA T32 Addictions Seminar, University of California San Diego, La Jolla, CA
- 2016 Pharmacotherapy for Alcohol Use Disorder; Veterans Administration San Diego Healthcare System/University of California San Diego (VASDHS/UCSD) Substance Use Disorders Seminar; La Jolla, CA; 2016
- 2015 A Translational Approach to Medication Development for Alcohol Dependence, NIAAA T32 Addictions Seminar, University of California San Diego, La Jolla, CA
- 2015 Novel Pharmacological Treatments for Alcohol Use Disorder; NIAAA T32 Addictions Seminar, University of California San Diego, La Jolla, CA
- 2015 Clinical Validation of Central Stress Systems as a Pharmacological Target in Treating Alcoholism; NIAAA T32 Addictions Seminar, University of California San Diego, La Jolla, CA

**The Scripps Research Institute:**

2016-present Course Director, “Neurobiology of Alcohol and Drug Addiction” Graduate Program, the Kellogg School of Science and Technology at The Scripps Research Institute

2004-present Supervised and mentored post-doctoral fellows in the Laboratory of Clinical Psychopharmacology at The Scripps Research Institute:

**Amanda Higley, Ph.D.** (2009-2012)

**Rebecca Crean, Ph.D.** (2006-2007)

**Tobie Escher, Ph.D.** (2004-2006)

*\*see Addendum: Table of Trainees*

2003-present Supervised and mentored pre-doctoral fellows in the Laboratory of Clinical Psychopharmacology at The Scripps Research Institute:

**Madeline Ng** (2018-present)

**Camila Paik** (2018-present)

**Audrey Chung** (2017-present)

**Shagun Gupta** (2017-2018)

**Amanda Stelter** (2016-2017)

**Amanda Solis** (2013-2018)  
**David Estey** (2013-2016)  
**Huayu Liu** (2013-2016)  
**Lauren Garufis** (2012-2013)  
**Vicky Chen** (2012-2013)  
**Tasha Wright** (2011-2012)  
**Katharine Caldwell** (2009-2012)  
**Marni Jacobs** (2008)  
**Natania Crane** (2008-2011)  
**Kanako Morikawa** (2007-2008)  
**Shawntel Payton** (2003-2007)  
*\*see Addendum: Table of Trainees*

**University of Miami Miller School of Medicine :**

- 1997-2003      Developed application and obtained ACGME accreditation for Addiction Psychiatry Fellowship Program, University of Miami School of Medicine
- 1997-2002      Developed and taught alcoholism module of PGY IV Psychopharmacology Seminar, University of Miami School of Medicine
- 1992-2002      Coordinated Substance Abuse Grand Rounds Series for the Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine
- 1992-2002      Developed and supervised substance abuse research elective program and served as research mentor for the following Psychiatry residents:

**Rodolfo A. Trivisonno, M.D.** (1996-1997)  
Relationship between subsyndromal depressive symptomatology and drinking in outpatient alcoholics

**Raymond L. Ownby, M.D., Ph.D.** (1995-1996)  
Travel Fellowship from NIAAA to attend Grantsmanship Training Workshop, Annapolis, MD; 1995  
American Psychiatric Association/Lilly Pharmaceuticals' Resident Research Award; 1995-1996  
Submitted FIRST AWARD application to NIAAA - Naltrexone and Coping Skills for Older Problem Drinkers

**Lauren Williams, M.D.**, Chief Resident (1994-1995)  
New Investigator Award, NIMH, New Clinical Drug Evaluation Unit (NCDEU); May 1995  
Travel Fellowship from NIAAA to attend Grantsmanship Training Workshop, Annapolis, MD; 1995  
R03 Award from NIAAA, No. 10627-01, Augmentation of Nalmefene in Alcoholism Treatment; start date April, 1995

Presented Grand Rounds on **The Maternal Addiction Program (MAP) of the University of Miami/Jackson Memorial Medical Center**, Department of Psychiatry, University of Miami School of Medicine  
Minority Investigator Supplement Award from NIAAA, No. R01 AA11210-02; \$290,617 total cost for 4 years (September, 1996-August, 2000)

**Antonio DeFilippo, M.D.** (1994-1995)  
Alcoholism and Obesity

**William Cua, M.D.** (1994)  
Clinical research elective on new treatments for alcoholism

**Emilio Mantero-Atienza, M.D.** (1994-1995)  
Travel Fellowship from NIAAA to attend Grantsmanship Training Workshop, Jacksonville, FL; July 1993  
Minority Investigator Supplement Award from NIAAA, R01 AA09560-01, \$154,000 total cost for 2 years (September 1993-August 31, 1995) to conduct dietary studies on alcoholics

**Fernando Salvato, M.D.** (1993-1994)  
Travel Fellowship from NIAAA to attend Grantsmanship Training Workshop, Jacksonville, FL; July 1993  
Minority Investigator Supplement Award from NIAAA, R01 AA09560-01, \$231,000 total cost for 3 years (September 1992-August 31, 1995)  
Presented Grand Rounds on **Substance Abuse**, Department of Psychiatry, University of Miami School of Medicine  
Minority Investigator Supplement Award from NIAAA, R01 AA10518, \$102,000 total cost for 1-1/2 years (December 1995 - April 1997)

**Evan Zimmer, M.D.** (1993-1994)  
Presented Grand Rounds on **Depression and Alcoholism**, Department of Psychiatry, University of Miami School of Medicine

**Bruce Welch, M.D.** (1992-1993)  
Collaborator on nalmefene in alcoholism pilot study

1992-2002 Critically discuss scientific papers for Psychiatry residents' Journal Club:

**Depression in Alcoholism**  
Presenter: Dr. Barbara Mason

**Prevalence of Substance Abuse Across Residency Specialties**  
Presenter: Dr. Thania Quesada

**Opiate Antagonist Treatment of Alcoholism**  
Presenter: Dr. Barry Kaplowitz

**Antidepressant Treatment of Alcoholism**  
Presenter: Dr. Yolanda Zarate

### **Lithium Treatment of Alcoholism**

Presenter: Dr. Isabel Jimenez

- 1991-2001 Developed the substance abuse teaching curriculum and conducted Substance Abuse seminars for PGY I and II Psychiatry residents, University of Miami School of Medicine
- 1994-1997 Faculty Advisor, INQUIRY: The Research Connection, a student organization matching University of Miami undergraduates with faculty research mentors, founded by Meena Garg during her undergraduate summer internship with Dr. Mason
- 1993-2002 Grand Rounds and didactic lectures for Department of Family Medicine residents, faculty, and staff, as requested, University of Miami School of Medicine
- 1993-1994 Sponsored Graduate Assistantship for **John Crout**, Department of Epidemiology
- 1993-1995 Sponsored interns participating in the University of Miami School of Medicine Summer Undergraduate Research Program  
**Meena Garg**, University of Miami, Miami  
Presented The Relationship Between Nicotine and Alcohol Dependence: Treatment Implications; University of Miami Summer Undergraduate Poster Session

**Ami Flam**, University of Michigan, Ann Arbor

**Jodi Eisner**, Cornell University, New York

Presented An Examination of Sex as a Predictor of Response to Pharmacotherapies; University of Miami School of Medicine Summer Undergraduate Poster Session

- 1992-2003 Developed and taught Substance Abuse module of Behavioral Sciences course for 1st Year Medical Students

### **Weill Cornell University Medical College:**

- 1983-1992 Research Associate to Assistant Professor; at various points taught Psychopathology course for medical students, lectured on alcoholism and affective disorders for Psychology interns and Psychiatry residents, coordinated affective disorders weekly seminar, developed and supervised research electives in the Alcohol Disorders Clinic for 3rd Year Psychiatry residents, Psychology graduate students, and medical student summer interns

### **Long Island University:**

- 1981-1984 Assistant Professor of Psychology; taught Ph.D. course in psychological assessment, and undergraduate courses in personality theories, abnormal psychology, behavior modification, and general psychology

## **VII. SERVICE:**

Member; Liaison Committee, American College of Neuropsychopharmacology (ACNP); 2016-2019

Member; Awards Committee, American College of Neuropsychopharmacology (ACNP); 2015

San Diego BRAIN Consortium (SDBC); Member, Scientific Advisory Board; 2014-2015

Member; Ad Hoc Promotions Committee, The Scripps Research Institute (TSRI); 2014

Member; External Advisory Committee, P50 Medications Development Center “Shared Pharmacotherapeutic Strategies for Cannabinoid and Opioid Use Disorders,” Columbia University Medical Center, New York, NY; 2013

Scientific Advisory Board, “Sativex Associated with Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence R21 DA031906,” Centre for Addiction and Mental Health, Toronto, ON; 2013-2015

Member; Program & Scientific Communications Committee, American College of Neuropsychopharmacology (ACNP); 2013-2015

Co-Chair; Program Committee, Research Society on Alcoholism (RSA); 2011

Member; Membership Committee, American College of Neuropsychopharmacology (ACNP); 2010-2012

Member; Library Advisory Committee, The Scripps Research Institute (TSRI); 2009-present

Chair; Ad Hoc Promotions Committee, The Scripps Research Institute (TSRI); 2008

Member; Education & Training Committee, American College of Neuropsychopharmacology (ACNP); 2006-2008

Member; Ethics Committee, American College of Neuropsychopharmacology (ACNP); 2001-2003

Member; Liaison Committee, American College of Neuropsychopharmacology (ACNP); 2000-2002, 2016-2018

Member; Pharmacologic Interventions and Publication Committees (1998), Steering Committee (1997-2008), Operations Committee (1997-1998), Behavioral Interventions Committee (1997-1998), Combined Behavioral / Pharmacologic Treatment of Alcoholism; Cooperative Agreement, NIAAA

Secretary; Research Society on Alcoholism; 1997-1999

Chair; Pharmacologic Interventions Committee, Combined Behavioral/Pharmacologic Treatment of Alcoholism; Cooperative Agreement, NIAAA; 1997-1998

Member; Scientific Advisory Committee for competitive renewal of NIAAA Alcohol Research Center, University of Connecticut; 1997



Consultant; NIAAA center grant renewal, and Member Scientific Advisory Committee, Alcohol Research Center, Medical University of South Carolina; 1996

Member; New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting of NIMH; Program Committee; 1994-1997

Scientific resource for print journalists, e.g., Wall Street Journal, New York Times, Forbes, Huffington Post, Chicago Tribune, New York Daily News, Boston Herald, USA Today, San Diego Union Tribune, Miami Herald, Sun-Sentinel, Montreal Gazette, Atlanta Journal and Constitution, Denver Post, Des Moines Register, Houston Chronicle, Palm Beach Post, Agence France Presse, Family Circle, Time Magazine, New Woman Magazine, American Medical News, etc.; and television reporters, e.g., NBC Today Show, CNN, ABC World News Tonight, NBC Nightly News, CBS and local news, on matters pertaining to alcoholism and drug addiction.